Positive Press Coverage Very Likely to Impact Amarin Corporation PLC (AMRN) Share Price
News articles about Amarin Corporation PLC (NASDAQ:AMRN) have been trending positive on Monday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amarin Corporation PLC earned a media sentiment score of 0.45 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 89 out of 100, indicating that recent news coverage is very likely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Amarin Corporation PLC (NASDAQ:AMRN) Earns “Buy” Rating from HC Wainwright (nolopodrasdejardever.com)
- Amarin Corporation plc (AMRN) Describing Technical Facts through Margin Ratios- New York REIT, Inc. (NYRT) – Investing News Update (investingbizz.com)
- Needle Action Activity Spotted in Amarin Corporation PLC (AMRN) – FLBC News (flbcnews.com)
- Amarin Corporation plc (AMRN) In Active Momentum Stocks on Ration Analysis- Grupo Televisa, SAB (TV) – Investing News Update (investingbizz.com)
- Amarin Corporation PLC (NASDAQ:AMRN) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
Amarin Corporation PLC (AMRN) opened at 4.17 on Monday. The company’s 50 day moving average is $3.09 and its 200 day moving average is $3.13. The stock’s market cap is $1.13 billion. Amarin Corporation PLC has a 52 week low of $2.19 and a 52 week high of $4.47.
Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The company had revenue of $34.60 million for the quarter, compared to analyst estimates of $37.85 million. The business’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.14) EPS. Equities analysts predict that Amarin Corporation PLC will post ($0.23) earnings per share for the current year.
A number of research firms have commented on AMRN. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a report on Wednesday, June 28th. BidaskClub upgraded shares of Amarin Corporation PLC from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Jefferies Group LLC lifted their target price on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, June 30th. Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. Finally, Cantor Fitzgerald set a $5.00 price target on shares of Amarin Corporation PLC and gave the company a “buy” rating in a research report on Monday, June 12th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Amarin Corporation PLC has an average rating of “Buy” and a consensus target price of $7.35.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/positive-press-coverage-very-likely-to-impact-amarin-corporation-plc-amrn-share-price/1444475.html.
In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of Amarin Corporation PLC stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total value of $1,231,644.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.72% of the stock is owned by insiders.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.